이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jubilant Pharmova 관리

관리 기준 확인 1/4

Jubilant Pharmova's CEO는 Priyavrat Bhartia, Jun2023 에 임명되었습니다 의 임기는 7.08 년입니다. 는 ₹ 1.02B 가치에 해당하는 회사 주식의 0.88% 직접 소유합니다. 1.02B. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 6.4 년입니다.

주요 정보

Priyavrat Bhartia

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.1yrs
CEO 소유권	0.9%
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	6.5yrs

최근 관리 업데이트

Recent updates

CEO

Priyavrat Bhartia (48 yo)

1.1yrs

테뉴어

Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...

리더십 팀

이름	위치	테뉴어	보상	소유권
Arvind Chokhany	Group CFO & Whole-Time Director	1.2yrs	₹53.43m	데이터 없음
Laxshmivarahan Ramasubramani	Group Chief Digital & Information Officer	no data	₹16.53m	데이터 없음
Naresh Kapoor	Company Secretary & Compliance Officer	1.9yrs	₹6.86m	데이터 없음
Praveen Gupta	Executive VP & Head of Direct Taxation	no data	₹21.06m	데이터 없음
K.V.S Kumar	Chief Sustainability Officer	no data	₹16.73m	데이터 없음
Priyavrat Bhartia	MD & Director	1.1yrs	데이터 없음	0.88% ₹ 1.0b
Arjun Bhartia	Joint MD & Director	1.1yrs	데이터 없음	데이터 없음
Prakash Bisht	Executive VP of Group Accounts	no data	데이터 없음	데이터 없음
Surajit Pal	Head of Investor Relations	no data	데이터 없음	데이터 없음
Sanjay Gupta	Executive VP & Head of Legal	9.7yrs	₹3.34m	데이터 없음
Shantanu Jha	Group Chief Human Resources Officer	1.5yrs	데이터 없음	데이터 없음
Rajagopal Sankaraiah	Advisor	4.3yrs	₹67.29m	데이터 없음

1.5yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 530019 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Arvind Chokhany	Group CFO & Whole-Time Director	3.3yrs	₹53.43m	데이터 없음
Priyavrat Bhartia	MD & Director	7.2yrs	데이터 없음	0.88% ₹ 1.0b
Arjun Bhartia	Joint MD & Director	7.2yrs	데이터 없음	데이터 없음
Arul Ramakrishan	Additional Director & Whole-time Director	less than a year	데이터 없음	데이터 없음
Shyam Sunder Bhartia	Chairman	46.1yrs	데이터 없음	0.084% ₹ 99.1m
Sushil Roongta	Independent Non-Executive Director	7.2yrs	₹1.76m	데이터 없음
Arun Seth	Independent Non-Executive Director	5.8yrs	₹1.38m	0.0013% ₹ 1.5m
Harsh Mahajan	Independent Director	less than a year	데이터 없음	데이터 없음
Hari Bhartia	Co-Chairman	40.7yrs	₹119.90m	0.23% ₹ 274.1m
Shivpriya Nanda	Independent Director	less than a year	데이터 없음	데이터 없음
Vivek Mehra	Independent Non-Executive Director	7.2yrs	₹1.85m	데이터 없음
Shirish Belapure	Additional Independent Non-Executive Director	1.3yrs	데이터 없음	데이터 없음

6.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 530019 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Jubilant Pharmova 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Recent updates

Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024

Full year 2024 earnings released: EPS: ₹4.84 (vs ₹3.83 loss in FY 2023)

Jubilant Pharmova Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Third quarter 2024 earnings released: EPS: ₹4.22 (vs ₹0.98 loss in 3Q 2023)

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Second quarter 2024 earnings released: EPS: ₹3.94 (vs ₹0.34 in 2Q 2023)

Price target decreased by 8.9% to ₹395

Jubilant Pharmova Limited to Report Fiscal Year 2024 Results on May 17, 2024

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹0.40 (vs ₹2.96 in 1Q 2023)

Jubilant Pharmova Limited to Report Fiscal Year 2023 Results on Jul 19, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Full year 2023 earnings released: ₹3.83 loss per share (vs ₹26.01 profit in FY 2022)

Jubilant Pharmova Limited to Report Q4, 2023 Results on May 29, 2023

Now 21% undervalued after recent price drop

Price target decreased by 11% to ₹384

Third quarter 2023 earnings released: ₹0.98 loss per share (vs ₹3.20 profit in 3Q 2022)

Jubilant Pharmova Limited to Report Q3, 2023 Results on Feb 03, 2023

Price target decreased to ₹391

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited to Report Q2, 2023 Results on Oct 21, 2022

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Price target decreased to ₹434

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before October 24, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Consensus forecasts updated

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹2.96 (vs ₹10.09 in 1Q 2022)

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited to Report Q1, 2023 Results on Aug 02, 2022

High number of new directors

Price target decreased to ₹507

Jubilant Pharmova Limited Approves Executive and Board Changes

Consensus EPS estimates fall by 18%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before September 7, 2022

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to ₹711

Second quarter 2022 earnings released: EPS ₹8.97 (vs ₹14.06 in 2Q 2021)

Price target decreased to ₹802

Price target decreased to ₹869

First quarter 2022 earnings released: EPS ₹10.09 (vs ₹5.53 in 1Q 2021)

Jubilant Pharmova Announces That the US FDA Has Placed Roorkee Facility Under Import Alert

Consensus revenue estimates fall to ₹65.7b

Full year 2021 earnings released: EPS ₹36.05 (vs ₹56.40 in FY 2020)

New 90-day low: ₹752

Price target raised to ₹1,021

Analysts update estimates

President of Manufacturing & Whole-Time Director Anant Pande has left the company

CEO of Life Science Ingredients & Whole-Time Director Rajesh Srivastava has left the company

Jubilant Pharmova Limited Announces Directorate Changes

Third quarter 2021 earnings released: EPS ₹13.75 (vs ₹12.77 in 3Q 2020)

Earnings beat expectations, revenue disappoints

New 90-day high: ₹1,026

Jubilant Life Sciences Limited to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: ₹978

New 90-day high: ₹866

Market bids up stock over the past week

New 90-day high: ₹820

New 90-day low: ₹683

Revenue and earnings miss expectations

Second quarter 2021 earnings released: EPS ₹14.06

Jubilant Life Sciences Limited to Report Q2, 2021 Results on Nov 04, 2020

Independent Non-Executive Director recently bought ₹1.1m worth of stock

Analysts lower EPS estimates to ₹55.56